Gapping up
In reaction to earnings/guidance:
- FRC +5.2%, TSM +1.7%
Other news:
- TBPH +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
- AMYT +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
- GRBK +7.3% (to join S&P SmallCap 600)
- TGA +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock strategic business combination)
- CLNN +5.9% (report significantly improved survival in ALS patients initially treated with CNM-Au8 compared to initially randomized placebo treated participants during the long-term open-label extension of its RESCUE-ALS trial)
- ANGI +5.6% (report June performance metrics)
- MRNS +5.4% (entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $110 mln)
- VCYT +4.2% (new data show that its GSC is highly accurate in re-classifying lung cancer risk)
- VCTR +2.6% (reports June AUM)
- DBRG +1.8% (acquires majority stake in GD Towers in partnership with Brookfield (BIP))
Analyst comments:
- FLYW +2.1% (upgraded to Buy from Neutral at Goldman)
- COST +0.8% (upgraded to Buy from Hold at Deutsche Bank)